Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Oral Bisphosphonate Exposure and the Risk of Upper Gastrointestinal Cancers.

Vogtmann E, Corley DA, Almers LM, Cardwell CR, Murray LJ, Abnet CC.

PLoS One. 2015 Oct 7;10(10):e0140180. doi: 10.1371/journal.pone.0140180. eCollection 2015.

2.

Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.

Jung SY, Sohn HS, Park EJ, Suh HS, Park JW, Kwon JW.

PLoS One. 2016 Mar 3;11(3):e0150531. doi: 10.1371/journal.pone.0150531. eCollection 2016.

3.

Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia.

Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyrén O.

J Natl Cancer Inst. 2004 Mar 3;96(5):388-96.

PMID:
14996860
4.

Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.

Oh YH, Yoon C, Park SM.

World J Gastroenterol. 2012 Oct 28;18(40):5779-88. doi: 10.3748/wjg.v18.i40.5779. Review.

5.

Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers.

Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, Mujumdar U, Ownby D, Wells K, Yood MU, Engel LS.

Clin Gastroenterol Hepatol. 2007 Oct;5(10):1154-1159.e3. Epub 2007 Jul 23.

6.

Metabolic syndrome and esophageal and gastric cancer.

Lin Y, Ness-Jensen E, Hveem K, Lagergren J, Lu Y.

Cancer Causes Control. 2015 Dec;26(12):1825-34. doi: 10.1007/s10552-015-0675-4. Epub 2015 Oct 8.

PMID:
26450604
7.
8.

Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux.

Vaughan TL, Farrow DC, Hansten PD, Chow WH, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Rotterdam H, Dubrow R, Ahsan H, West AB, Blot WJ, Fraumeni JF Jr.

Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56.

9.

Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the General Practice Research Database (GPRD).

Wright E, Schofield PT, Seed P, Molokhia M.

PLoS One. 2012;7(10):e47616. doi: 10.1371/journal.pone.0047616. Epub 2012 Oct 24.

10.

Occupational exposures and risk of esophageal and gastric cardia cancers among male Swedish construction workers.

Jansson C, Johansson AL, Bergdahl IA, Dickman PW, Plato N, Adami J, Boffetta P, Lagergren J.

Cancer Causes Control. 2005 Aug;16(6):755-64.

PMID:
16049815
11.

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.

Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V.

BMJ. 2010 Sep 1;341:c4444. doi: 10.1136/bmj.c4444.

12.

Abdominal obesity and the risk of esophageal and gastric cardia carcinomas.

Corley DA, Kubo A, Zhao W.

Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8. doi: 10.1158/1055-9965.EPI-07-0748.

13.

Association between body mass and adenocarcinoma of the esophagus and gastric cardia.

Lagergren J, Bergström R, Nyrén O.

Ann Intern Med. 1999 Jun 1;130(11):883-90.

PMID:
10375336
14.

Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.

Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W, Lagergren J.

Br J Cancer. 2006 Jul 3;95(1):118-22. Epub 2006 Jun 6.

15.

Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury.

Morden NE, Munson JC, Smith J, Mackenzie TA, Liu SK, Tosteson AN.

Osteoporos Int. 2015 Feb;26(2):663-72. doi: 10.1007/s00198-014-2925-9. Epub 2014 Oct 28.

16.

Family history of cancer and risk of esophageal and gastric cancers in the United States.

Dhillon PK, Farrow DC, Vaughan TL, Chow WH, Risch HA, Gammon MD, Mayne ST, Stanford JL, Schoenberg JB, Ahsan H, Dubrow R, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr.

Int J Cancer. 2001 Jul 1;93(1):148-52.

17.

Nutrient intake and risk of subtypes of esophageal and gastric cancer.

Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, Farrow DC, Schoenberg JB, Stanford JL, Ahsan H, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr.

Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62.

18.

Prospective study of tooth loss and incident esophageal and gastric cancers in China.

Abnet CC, Qiao YL, Mark SD, Dong ZW, Taylor PR, Dawsey SM.

Cancer Causes Control. 2001 Nov;12(9):847-54.

PMID:
11714113
19.
20.

Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ.

J Natl Cancer Inst. 2011 Jul 6;103(13):1049-57. doi: 10.1093/jnci/djr203. Epub 2011 Jun 16. Erratum in: J Natl Cancer Inst. 2013 Apr 17;105(8):581.

Supplemental Content

Support Center